# US 2013/0158003 A1 · Heteroaryl compounds and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158003 A1
- Document ID: US20130158003A1
- Status: Published application
- Kind: A1
- Application number: 13/700,051
- Filed: 2011-05-26
- Published: 2013-06-20
- Earliest claimed: 2010-05-26
- Assignees: Sunovion Pharmaceuticals Inc.
- Inventors: John Emmerson Campbell; Michael Charles Hewitt; Philip Jones; Linghong Xie
- Web page: https://patentgrep.com/patent/US20130158003A1

## CPC

- C07D 498/06: Peri-condensed systems
- A61K 31/4164: 1,3-Diazoles
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/5383: ortho- or peri-condensed with heterocyclic ring systems
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 233/58: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/14: containing three or more hetero rings
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/14: containing three or more hetero rings
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 409/14: containing three or more hetero rings
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 471/04: Ortho-condensed systems
- C07D 471/06: Peri-condensed systems
- C07D 471/14: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 491/056: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C07D 498/04: Ortho-condensed systems
- C07D 498/14: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

## Claims

### Claim 1

A compound of formula (I):
A-L-B (I),
or a pharmaceutically acceptable salt or stereoisomer thereof, wherein
L is —C(R6)2—C(R6)2—, —C(R6)═C(R6) —, —N(R10) —C(R6)2—, —O—C(R6)2—, —C(R6)2—N(R10) —, —C(R6)2—O—, —C(R6)2—S—, —S—, —(CH2)p—S—(CH2)q—, or —(CH2)u—;
A is
B is
-A1-A2- is —NR7—C(═O) —, —C(═O)—NR7—, —O—C(═O) —, —C(═O)—O—, —N═CR8—, —CR8═N—, —CR8═CR8—, or —N═N—;
A3 is N or CR9;
A4 is NR5, O, or S;
A5 is CR5 or N;
A6 is N or CR5;
R1 and R2 are each independently (i) hydrogen, cyano, or halo; or (ii) (C1-C10)alkyl, (C2-C10)alkenyl, (C1-C10)alkoxyl, (C1-C10)aminoalkyl, (C1-C10)heteroalkyl, (C3-C10)cycloalkyl, (6 to 10 membered)aryl, (5 to 10 membered)heteroaryl, (3 to 12 membered)heterocyclyl, hydroxyl, amino, imino, amido, carbonyl, thiol, sulfinyl, or sulfonyl, each of which is optionally substituted with one or more R11; or (iii) R1 and R2 together with the carbon atoms to which they are attached form a ring optionally substituted with one or more R11;
R3 and R4 are each independently (i) hydrogen, cyano, or halo; or (ii) (C1-C10)alkyl, (C2-C10)alkenyl, (C1-C10)alkoxyl, (C1-C10)aminoalkyl, (C1-C10)heteroalkyl, (C3-C10)cycloalkyl, (6 to 10 membered)aryl, (5 to 10 membered)heteroaryl, (3 to 12 membered)heterocyclyl, hydroxyl, amino, imino, amido, carbonyl, thiol, sulfinyl, or sulfonyl, each of which is optionally substituted with one or more R11; or (iii) R3 and R4 together with the atoms to which they are attached form a ring optionally substituted with one or more R11;
R5 is (i) hydrogen, cyano, or halo; or (ii) (C1-C10)alkyl, (C2-C10)alkenyl, (C1-C10)alkoxyl, (C1-C10)aminoalkyl, (C1-C10)heteroalkyl, (C3-C10)cycloalkyl, (6 to 10 membered)aryl, (5 to 10 membered)heteroaryl, (3 to 12 membered)heterocyclyl, hydroxyl, amino, imino, amido, carbonyl, thiol, sulfinyl, or sulfonyl, each of which is optionally substituted with one or more R11; or (iii) R4 and R5 together with the atoms to which they are attached form a ring optionally substituted with one or more R11;
R19 is (i) hydrogen, cyano, or halo; or (ii) (C1-C10)alkyl, (C2-C10)alkenyl, (C1-C10)alkoxyl, (C1-C10)aminoalkyl, (C1-C10)heteroalkyl, (C3-C10)cycloalkyl, (6 to 10 membered)aryl, (5 to 10 membered)heteroaryl, (3 to 12 membered)heterocyclyl, hydroxyl, amino, imino, amido, carbonyl, thiol, sulfinyl, or sulfonyl, each of which is optionally substituted with one or more R11;
R20 is (i) hydrogen; or (ii) (C1-C10)alkyl, (C2-C10)alkenyl, (C1-C10)heteroalkyl, (C3-C10)cycloalkyl, (6 to 10 membered)aryl, (5 to 10 membered)heteroaryl, (3 to 12 membered)heterocyclyl, carbonyl, or sulfonyl, each of which is optionally substituted with one or more R11;
each occurrence of R6 is independently hydrogen, halo, or (C1-C6)alkyl optionally substituted with one or more halo;
R7 is hydrogen or (C1-C6)alkyl optionally substituted with one or more halo;
each occurrence of R8 is independently (i) hydrogen, cyano, or halo; or (ii) (C1-C10)alkyl, (C2-C10)alkenyl, (C1-C10)alkoxyl, (C1-C10)aminoalkyl, (C1-C10)heteroalkyl, (C3-C10)cycloalkyl, (6 to 10 membered)aryl, (5 to 10 membered)heteroaryl, (3 to 12 membered) heterocyclyl, hydroxyl, amino, imino, amido, carbonyl, thiol, sulfinyl, or sulfonyl, each of which is optionally substituted with one or more R11;
R9 is hydrogen, cyano, halo, (C1-C6)alkyl optionally substituted with one or more halo, or (C1-C6)alkoxyl optionally substituted with one or more halo;
R10 is hydrogen or (C1-C6)alkyl optionally substituted with one or more halo;
each occurrence of R11 is independently hydrogen, halogen, cyano, ═O, —OR13, —NR13R14, —N(R13)C(O)R14, —C(O)NR13R14, —C(O)R13, —C(O)OR13, —OC(O)R13, —SR13, —S(O)R13, —S(O)2R13, —S(O)2NR13R14, C1-C10)alkyl optionally substituted with one or more R12, (C1-C10)heteroalkyl optionally substituted with one or more R12, (C3-C10)cycloalkyl optionally substituted with one or more R12, (C7-C12)aralkyl optionally substituted with one or more R12, (C3-C12)heteroaralkyl optionally substituted with one or more R12, (6 to 10 membered)aryl optionally substituted with one or more R12, (5 to 10 membered)heteroaryl optionally substituted with one or more R12, or (3 to 12 membered)heterocyclyl optionally substituted with one or more R12;
each occurrence of R12 is independently hydrogen, (C1-C6)alkyl optionally substituted with one or more R13, (C3-C6)cycloalkyl optionally substituted with one or more R13, halogen, cyano, ═O, —OR13, —NR13R14, —N(R13)C(O)R14, —C(O)NR13R14, —C(O)R13, —C(O)OR13, —OC(O)R13, —SR13, —S(O)R13, —S(O)2R13, or —S(O)2NR13R14;
each occurrence of R13 and R14 is independently hydrogen, (C1-C6)alkyl, (C1-C6) heteroalkyl, (C3-C6)cycloalkyl, (C7-C10)aralkyl; (C3-C12)heteroaralkyl, (6 to 10 membered)aryl, (5 to 10 membered)heteroaryl, or (3 to 12 membered)heterocyclyl; or R13 and R14 together may form a 3 to 10 membered ring; and
u is 2 or 3; and
p and q are each independently 0, 1, or 2, provided that when one of p and q is 0, the other is 1 or 2.

### Claim 2 (depends on 1)

The compound of claim 1, wherein L is —CH2—CH2—, —CH═CH—, —O—CH2—, —NH—CH2—, —CH2—NH—, —CH2—S—, or —S—.

### Claim 3 (depends on 2)

The compound of claim 2, wherein L is —CH2—CH2—.

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, having formula (I-A):

### Claim 5 (depends on 4)

The compound of claim 4, wherein A4 is NR5; and R5 is (i) hydrogen; or (ii) (C1-C10)alkyl, (C2-C10)alkenyl, (C1-C10)heteroalkyl, (C3-C10)cycloalkyl, (6 to 10 membered) aryl, (5 to 10 membered) heteroaryl, (3 to 12 membered)heterocyclyl, carbonyl, or sulfonyl, each of which is optionally substituted with one or more R11; or (iii) R4 and R5 together with the atoms to which they are attached form a ring optionally substituted with one or more R11.

### Claim 6 (depends on 5)

The compound of claim 5, wherein R5 is H or CH3.

### Claim 7 (depends on 4)

The compound of claim 4, wherein
k is 0, 1, 2, 3, or 4;
each occurrence of G is independently CH or N; and
J is O, S, NH or CH2.

### Claim 8 (depends on 7)

The compound of claim 7, wherein R3 is (i) hydrogen; or (ii) alkyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R11.

### Claim 9 (depends on 7)

The compound of claim 7, wherein R4 is (i) hydrogen; or (ii) alkyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R11.

### Claim 10 (depends on 7)

The compound of claim 7, wherein R5 is (i) hydrogen; or (ii) alkyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R11.

### Claim 11 (depends on 7)

The compound of claim 7, wherein each occurrence of R11 is independently (i) hydrogen; or (ii) alky, aryl or heteroaryl, each of which is optionally substituted with one or more R12.

### Claim 12 (depends on 4)

The compound of claim 4, wherein

### Claim 13 (depends on 4)

The compound of claim 4, wherein the compound is:

### Claim 14 (depends on 4)

The compound of any claim 4, wherein R1 and R2 together with the carbon atoms to which they are attached form an optionally substituted pyridyl ring.

### Claim 15 (depends on 14)

The compound of claim 14, wherein the compound is:

### Claim 16 (depends on 4)

The compound of claim 4, wherein
each occurrence of R15 is independently: (i) hydrogen, halo, cyano, —OR13, —NR13R14, —N(R13)C(O)R14, —C(O)NR13R14, —C(O)R13, —C(O)OR13, —OC(O)R13, —SR13, —S(O)R13, —S(O)2R13, —S(O)2NR13R14, (C1-C10)alkyl optionally substituted with one or more R12, (C1-C10)heteroalkyl optionally substituted with one or more R12, (C3-C10)cycloalkyl optionally substituted with one or more R12, (C7-C12)aralkyl optionally substituted with one or more R12, (C3-C12)heteroaralkyl optionally substituted with one or more R12, (6 to 10 membered)aryl optionally substituted with one or more R12, (5 to 10 membered)heteroaryl optionally substituted with one or more R12, or (3 to 12 membered)heterocyclyl optionally substituted with one or more R12; or (ii) when two occurrences of R15 are attached to adjacent carbon atoms, the two adjacent occurrences of R15 together with the carbon atoms to which they are attached may form a ring, optionally substituted with one or more R11; and
m is 0, 1, 2, 3, or 4.

### Claim 17 (depends on 16)

The compound of claim 16, wherein R8 is hydrogen or methyl.

### Claim 18 (depends on 16)

The compound of claim 16, wherein the compound is:

### Claim 19 (depends on 4)

The compound of claim 4, wherein
each occurrence of R15 is independently: (i) hydrogen, halo, cyano, —OR13, —NR13R14, —N(R13)C(O)R14, —C(O)NR13R14, —C(O)R13, —C(O)OR13, —OC(O)R13, —SR13, —S(O)R13, —S(O)2R13, —S(O)2NR13R14, (C1-C10)alkyl optionally substituted with one or more R12, (C1-C10)heteroalkyl optionally substituted with one or more R12, (C3-C10)cycloalkyl optionally substituted with one or more R12, (C7-C12)aralkyl optionally substituted with one or more R12, (C3-C12)heteroaralkyl optionally substituted with one or more R12, (6 to 10 membered)aryl optionally substituted with one or more R12, (5 to 10 membered)heteroaryl optionally substituted with one or more R12, or (3 to 12 membered)heterocyclyl optionally substituted with one or more R12; or (ii) when two occurrences of R15 are attached to adjacent carbon atoms, the two adjacent occurrences of R15 together with the carbon atoms to which they are attached may form a ring, optionally substituted with one or more R11; and
m is 0, 1, 2, 3, or 4.

### Claim 20 (depends on 19)

The compound of claim 19, wherein the compound is:

### Claim 21 (depends on 4)

The compound of claim 4, wherein
each occurrence of R15 is independently: (i) hydrogen, halo, cyano, —OR13, —NR13R14, —N(R13)C(O)R14, —C(O)NR13R14, —C(O)R13, —C(O)OR13, —OC(O)R13, —SR13, —S(O)R13, —S(O)2R13, —S(O)2NR13R14, (C1-C10)alkyl optionally substituted with one or more R12, (C1-C10)heteroalkyl optionally substituted with one or more R12, (C3-C10)cycloalkyl optionally substituted with one or more R12, (C7-C12)aralkyl optionally substituted with one or more R12, (C3-C12)heteroaralkyl optionally substituted with one or more R12, (6 to 10 membered)aryl optionally substituted with one or more R12, (5 to 10 membered)heteroaryl optionally substituted with one or more R12, or (3 to 12 membered)heterocyclyl optionally substituted with one or more R12; or (ii) when two occurrences of R15 are attached to adjacent carbon atoms, the two adjacent occurrences of R15 together with the carbon atoms to which they are attached may form a ring, optionally substituted with one or more R11; and
m is 0, 1, 2, 3, or 4.

### Claim 22 (depends on 21)

The compound of claim 21, wherein the compound is:

### Claim 23 (depends on 4)

The compound of claim 4, wherein
A2 is NH, NCH3, or O;
each occurrence of R15 is independently: (i) hydrogen, halo, cyano, —OR13, —NR13R14, —N(R13)C(O)R14, —C(O)NR13R14, —C(O)R13, —C(O)OR13, —OC(O)R13, —SR13, —S(O)R13, —S(O)2R13, —S(O)2NR13R14, C1-C10)alkyl optionally substituted with one or more R12, (C1-C10)heteroalkyl optionally substituted with one or more R12, (C3-C10)cycloalkyl optionally substituted with one or more R12, (C7-C12)aralkyl optionally substituted with one or more R12, (C3-C12)heteroaralkyl optionally substituted with one or more R12, (6 to 10 membered)aryl optionally substituted with one or more R12, (5 to 10 membered)heteroaryl optionally substituted with one or more R12, or (3 to 12 membered)heterocyclyl optionally substituted with one or more R12; or (ii) when two occurrences of R15 are attached to adjacent carbon atoms, the two adjacent occurrences of R15 together with the carbon atoms to which they are attached may form a ring, optionally substituted with one or more R11; and
m is 0, 1, 2, 3, or 4.

### Claim 24 (depends on 23)

The compound of claim 23, wherein the compound is:

### Claim 25 (depends on 1)

The compound of claim 1, wherein
A is
B is
A5 is CR5;
R3 and R4 together with the atoms to which they are attached form an optionally substituted ring.

### Claim 26 (depends on 25)

The compound of claim 25, wherein R5 is H or CH3.

### Claim 27 (depends on 25)

The compound of claim 25, wherein the compound is:

### Claim 28 (depends on 1)

The compound of claim 1, wherein
A is
B is
wherein each R11 may be the same or different.

### Claim 29 (depends on 28)

The compound of claim 28, wherein the compound is:

### Claim 30 (depends on 1)

A compound of claim 1, having formula (I-B):
D-L-E (I-B)
or a pharmaceutically acceptable salt or stereoisomer thereof, wherein
L is —(CH2)u—, —CH═CH—, or —(CH2)p—S—(CH2)q—;
D is
E is
X is N or CR26;
each Y is independently N or CR;
each Z is independently N or C;
Q is independently N or CR25;
provided that D contains 1, 2, 3, or 4 nitrogen ring atoms;
each occurrence of R is independently hydrogen, halo, cyano, (C1-C6)alkyl, (C1-C6)alkoxyl, (C1-C6)hydroxyalkyl, aryl, or heteroaryl; each of which is optionally substituted;
R25 is hydrogen, halo, cyano, (C1-C6)alkyl, (C3-C8)cycloalkyl, (C1-C6)alkoxyl, (C1-C6)hydroxyalkyl, CH2CN, CH2C(O)NH2, (C7-C12)aralkyl, or alkyl-heterocycloalkyl; each of which is optionally substituted;
R26 and R27 are independently hydrogen, halo, cyano, (C1-C6)alkyl, (C1-C6)alkoxyl, aryl, or heteroaryl; each of which is optionally substituted; or R26 and R27 together with the atoms to which they are attached form an optionally substituted cycloalkyl, aryl, heteroaryl, or heterocyclyl ring;
u is 2 or 3; and
p and q are each independently 0, 1, or 2, provided that when one of p and q is 0, the other is 1 or 2.

### Claim 31 (depends on 30)

The compound of claim 30, wherein E is:
wherein
Y1 is N or CR21; Y2 is N or CR22; Y3 is N or CR23; and Y4 is N or CR24; provided that at least one of Y1, Y2, Y3, and Y4 is not N;
Z1 is N, O, S, CR21, or NR21; Z2 is N, O, S, CR22, or NR22; and Z3 is N, O, S, CR23, or NR23; provided that Z1, Z2, and Z3 together with the carbon atoms to which they are attached form a stable 5-membered heteroaryl;
each occurrence of R21, R22, R23, and R24 is independently hydrogen, halo, cyano, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)heteroalkyl, (C1-C6)alkoxyl, (C1-C6)aminoalkyl, (C1-C6)hydroxyalkyl, CH2CN, CH2C(O)NH2, (C3-C8)cycloalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroaralkyl, or alkyl-heterocycloalkyl; each of which is optionally substituted; and
two adjacent R21, R22, R23, and R24 may together with the atoms to which they are attached form an optionally substituted aromatic or non-aromatic ring.

### Claim 32 (depends on 30)

The compound of claim 30, wherein L is —CH2—CH2—, —CH2—CH2—CH2—, —S—CH2—, —CH2—S—, —CH═CH—, —S—CH2—CH2—, —CH2—S—CH2—, or —CH2—CH2—S—.

### Claim 33 (depends on 32)

The compound of claim 32, wherein L is —CH2—CH2, —CH2—CH2—CH2—, or —CH═CH—.

### Claim 34 (depends on 33)

The compound of claim 33, wherein L is —CH2—CH2—.

### Claim 35 (depends on 30)

The compound of claim 30, wherein D is:

### Claim 36 (depends on 35)

The compound of claim 35, wherein D is:

### Claim 37 (depends on 30)

The compound of claim 30, wherein E is:

### Claim 38 (depends on 30)

The compound of claim 30, wherein E is:
wherein one of Y1, Y2, Y3, and Y4 is nitrogen and the other three of Y1, Y2, Y3, and Y4 are substituted carbon.

### Claim 39 (depends on 30)

The compound of claim 30, wherein the compound is:

### Claim 40

A compound, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound is:

### Claim 41 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof 42-43. (canceled)

### Claim 44 (depends on 1)

A method of treating a disorder selected from a CNS disorder, a metabolic disorder, a neurological disorder, schizophrenia, schizophrenia-related disorders, schizophrenia spectrum disorder, acute schizophrenia, chronic schizophrenia, NOS schizophrenia, schizoaffective disorder, schizophreniform disorder, paraphrenia, paranoid personality disorder, schizoid personality disorder, schizotypal personality disorder, delusional disorder, psychosis, disease having a psychosis component, psychotic disorder, brief psychotic disorder, Alzheimer's psychosis, Parkinson's psychosis, shared psychotic disorder, substance-induced psychotic disorder, psychotic disorder due to a general medical condition, psychoaffective disorder, aggression, delirium, excitative psychosis, Tourette's syndrome, manic disorder, organic psychosis, NOS psychosis, convulsion, seizure, agitation, posttraumatic stress disorder, behavior disorder, neurodegenerative disease, Huntington's disease, Alzheimer's disease, Parkinson's disease, dyskinesia, dementia, mood disorder, bipolar disorder, anxiety, depression, major depressive disorder, unipolar depression, treatment resistant depression, dysthymia, affective disorder, seasonal affective disorder, obsessive-compulsive disorder, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), vertigo, pain, neuropathic pain, sensitization accompanying neuropathic pain, inflammatory pain, fibromyalgia, migraine, cognitive impairment, cognitive impairment associated with schizophrenia, cognitive deficit in Alzheimer's disease, cognitive deficit in Parkinson's disease, movement disorder, restless leg syndrome (RLS), multiple sclerosis, sleep disorder, substance abuse or dependency, addiction, eating disorder, autism, obesity, undesirable weight retention or weight gain, metabolic syndrome, diabetes, non-insulin dependent diabetes, impaired glucose tolerance, and hyperglycemia, comprising administering to a subject a therapeutically or prophylactically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim at position 43

45-48. (canceled)
